Overview
- STAT News reported that a 79-year-old, high-profile man was approved for compassionate-use access to retatrutide, an investigational weight‑loss drug, based on three anonymous sources who said the approval occurred in 2025.
- The White House issued a clear denial that the compassionate‑use patient was President Trump, with senior deputy press secretary Kush Desai calling the suggestion false.
- President Trump abruptly canceled a planned signing for the bipartisan 21st Century ROAD to Housing Act and posted about the cancellation on Truth Social on Wednesday, prompting renewed attention to the STAT report.
- Rep. Ted Lieu publicly tied the cancellation and cited observed symptoms—sleepiness, arm weakness, hand swelling—as reasons the White House should explain the president’s condition, and White House communications director Steven Cheung sharply attacked Lieu.
- There is no independent public confirmation that Trump received retatrutide or has a terminal illness, and the compassionate‑use pathway cited in reporting is normally used only for patients with serious or life‑threatening conditions, which is why lawmakers are seeking more transparency.